revealed that MUC16 inhibits ADCC by binding with antibodies and suppressing Fc-γ receptor activation, with patients having low MUC16 levels in recurrent platinum-sensitive ovarian cancer showing improved survival following farletuzumab treatment compared to a control group (91). Here, MUC16 is linked to ovarian carcinoma.